Editorial
Tailor the adjuvant hormonal manipulation for premenopausal breast cancer patients
Translational Cancer Research
2016;
5
(Suppl 3)
:S380-S384
.
(29 September 2016)
Adjuvant chemotherapy for locally advanced bladder cancer—a step closer to ending the ongoing controversy
Translational Cancer Research
2016;
5
(Suppl 3)
:S385-S386
.
(29 September 2016)
More is not always better: clinical genetics of familial breast cancer in the era of massively enhanced sequencing capacities
Translational Cancer Research
2016;
5
(Suppl 3)
:S387-S391
.
(29 September 2016)
Akt1/Akt2 inhibition and development of hepatocellular carcinoma
Translational Cancer Research
2016;
5
(Suppl 3)
:S392-S394
.
(29 September 2016)
Mutational and transcriptome based sub-classification of pancreatic cancer: are we there yet?
Translational Cancer Research
2016;
5
(Suppl 3)
:S395-S399
.
(29 September 2016)
A lovely leap toward the development of breast cancer therapy with long non-coding RNAs
Translational Cancer Research
2016;
5
(Suppl 3)
:S400-S404
.
(29 September 2016)
Multimodality imaging for early assessment of head and neck patients during induction chemotherapy: a reliable future option?
Translational Cancer Research
2016;
5
(Suppl 3)
:S405-S407
.
(29 September 2016)
Immune checkpoint blockade (ICB) for first line treatment in non-small-cell lung cancer (NSCLC)
Translational Cancer Research
2016;
5
(Suppl 3)
:S408-S410
.
(29 September 2016)
Post radiofrequency ablation assessment of colorectal cancer liver metastases—does post ablation biopsy really matter?
Translational Cancer Research
2016;
5
(Suppl 3)
:S411-S414
.
(29 September 2016)
The CROSS road in neoadjuvant therapy for esophageal cancer: long-term results of CROSS trial
Translational Cancer Research
2016;
5
(Suppl 3)
:S415-S419
.
(29 September 2016)
Personalized molecular targeted therapy for hepatocellular carcinoma in the era of genome sequencing
Translational Cancer Research
2016;
5
(Suppl 3)
:S420-S424
.
(29 September 2016)
Afatinib and gefitinib: a direct comparison
Translational Cancer Research
2016;
5
(Suppl 3)
:S425-S427
.
(29 September 2016)
Another important step towards understanding tumor immune evasion—novel mechanisms of PD-L1 overexpression
Translational Cancer Research
2016;
5
(Suppl 3)
:S428-S432
.
(29 September 2016)
Balancing redox stress: anchorage-independent growth requires reductive carboxylation
Translational Cancer Research
2016;
5
(Suppl 3)
:S433-S437
.
(29 September 2016)
Chemo-radiotherapy free conditioning regimen: immunotoxin at its magical best
Translational Cancer Research
2016;
5
(Suppl 3)
:S438-S443
.
(29 September 2016)
Novel toxicology challenges in the era of chimeric antigen receptor T-cells therapies
Translational Cancer Research
2016;
5
(Suppl 3)
:S444-S449
.
(29 September 2016)
Should we incorporate ablative radiotherapy in standard treatment of advanced intrahepatic cholangiocarcinoma?
Translational Cancer Research
2016;
5
(Suppl 3)
:S450-S453
.
(29 September 2016)
Durvalumab (MEDI4736; anti-PD-L1 inhibitor): to shed light on the treatment of advanced urothelial bladder cancer patients refractory to systemic chemotherapy
Translational Cancer Research
2016;
5
(Suppl 3)
:S454-S457
.
(29 September 2016)
Expanding therapies for crizotinib refractory ALK-rearranged nonsmall cell lung cancer
Translational Cancer Research
2016;
5
(Suppl 3)
:S458-S461
.
(29 September 2016)
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that?
Translational Cancer Research
2016;
5
(Suppl 3)
:S462-S466
.
(29 September 2016)
BIRC3 as a yet underestimated prognostic marker of malignancies?
Translational Cancer Research
2016;
5
(Suppl 3)
:S467-S469
.
(29 September 2016)
Atezolizumab in lung cancer—appreciating the differences
Translational Cancer Research
2016;
5
(Suppl 3)
:S470-S473
.
(29 September 2016)
Pushing the limits in pancreatic cancer therapy
Translational Cancer Research
2016;
5
(Suppl 3)
:S474-S476
.
(29 September 2016)
Perspective
Program death-1 (PD-1) receptor pathway inhibition in cancer medicine: a perspective on clinical efficacy and associated toxicities
Translational Cancer Research
2016;
5
(Suppl 3)
:S477-S484
.
(29 September 2016)
The STAMPEDE trial: paradigm-changing data through innovative trial design
Translational Cancer Research
2016;
5
(Suppl 3)
:S485-S490
.
(29 September 2016)
Pharmacological management update: clinical significance of anamorelin clinical trials for the treatment of cancer cachexia in advanced cancer patients
Translational Cancer Research
2016;
5
(Suppl 3)
:S491-S496
.
(29 September 2016)
Activation of calcineurin in cancer: many paths, one hub
Translational Cancer Research
2016;
5
(Suppl 3)
:S497-S506
.
(29 September 2016)
Feed your gut with caution!
Translational Cancer Research
2016;
5
(Suppl 3)
:S507-S513
.
(29 September 2016)
Regulation of chemo-sensitivity in ovarian cancer via a stroma dependent glutathione pathway
Translational Cancer Research
2016;
5
(Suppl 3)
:S514-S519
.
(29 September 2016)
Intracranial efficacy of crizotinib versus chemotherapy in PROFILE 1014: shining a light on central nervous system endpoints in clinical trials
Translational Cancer Research
2016;
5
(Suppl 3)
:S520-S525
.
(29 September 2016)
Research Highlight
Butyrate consumption of differentiated colonocytes in the upper crypt promotes homeostatic proliferation of stem and progenitor cells near the crypt base
Translational Cancer Research
2016;
5
(Suppl 3)
:S526-S528
.
(29 September 2016)
Commentary
Directing abiraterone metabolism: balancing the scales between clinical relevance and experimental observation
Translational Cancer Research
2016;
5
(Suppl 3)
:S529-S531
.
(29 September 2016)
Immune checkpoint inhibitors in non-small cell lung cancer: is simultaneous blockade better?
Translational Cancer Research
2016;
5
(Suppl 3)
:S532-S535
.
(29 September 2016)
Colonic crypts are natural gatekeepers of microbial metabolites to protect stem cells
Translational Cancer Research
2016;
5
(Suppl 3)
:S536-S539
.
(29 September 2016)
Theranostic siRNA conjugated nanoparticles: the possible central role of superparagmetic iron oxide nanoparticles as a new transfer vehicle system for therapy and diagnostic in human cancer therapy
Translational Cancer Research
2016;
5
(Suppl 3)
:S540-S543
.
(29 September 2016)
Mastectomy in precision oncology era: myth or reality?
Translational Cancer Research
2016;
5
(Suppl 3)
:S544-S545
.
(29 September 2016)
Some aspects of mutant p53 in ovarian cancer biology
Translational Cancer Research
2016;
5
(Suppl 3)
:S546-S547
.
(29 September 2016)
Commentary on a randomized controlled trial of vagus nerve- preserving distal gastrectomy in early gastric cancer
Translational Cancer Research
2016;
5
(Suppl 3)
:S548-S550
.
(29 September 2016)
Drivers of neuroendocrine prostate cancer
Translational Cancer Research
2016;
5
(Suppl 3)
:S551-S553
.
(29 September 2016)
Crizotinib for ALK rearrangement-positive non-small cell lung cancer patients with central nervous system metastasis
Translational Cancer Research
2016;
5
(Suppl 3)
:S554-S556
.
(29 September 2016)
Helicobacter pylori vacuolating cytotoxin and gastric cancer risk: reconsidered
Translational Cancer Research
2016;
5
(Suppl 3)
:S557-S560
.
(29 September 2016)
Extracellular vesicles in cancer: current status and challenges
Translational Cancer Research
2016;
5
(Suppl 3)
:S561-S563
.
(29 September 2016)
Long non-coding RNAs: new opportunities and old challenges in cancer therapy
Translational Cancer Research
2016;
5
(Suppl 3)
:S564-S566
.
(29 September 2016)
GAS5 oligonucleotides as therapeutic agents in breast cancer
Translational Cancer Research
2016;
5
(Suppl 3)
:S567-S568
.
(29 September 2016)
Estrogen receptor and human epidermal growth factor receptor-2 quantification and efficacy to trastuzumab
Translational Cancer Research
2016;
5
(Suppl 3)
:S569-S571
.
(29 September 2016)
ETV1 combines tumor cell plasticity with constitution of a pro-tumorigenic stroma in pancreatic cancer
Translational Cancer Research
2016;
5
(Suppl 3)
:S572-S573
.
(29 September 2016)
Video-assisted thoracoscopic surgery or open thoracotomy approach for surgery for non-small cell lung cancer—no definitive answer, yet
Translational Cancer Research
2016;
5
(Suppl 3)
:S574-S575
.
(29 September 2016)
Predicting the response to anti-PD1 therapy in metastatic melanoma
Translational Cancer Research
2016;
5
(Suppl 3)
:S576-S579
.
(29 September 2016)
Oncogenic combined calcineurin-nuclear factor of activated T cells and toll-like receptor signals in colon
Translational Cancer Research
2016;
5
(Suppl 3)
:S580-S583
.
(29 September 2016)
The role of the liquid biopsy as a clinical tool for early prediction in prostate cancer
Translational Cancer Research
2016;
5
(Suppl 3)
:S584-S586
.
(29 September 2016)
Cyclin dependent kinase 5—a novel target to enhance the antitumor immune response
Translational Cancer Research
2016;
5
(Suppl 3)
:S587-S589
.
(29 September 2016)
Bendamustine and rituximab for the treatment of relapsed indolent and mantle cell lymphoma: when timing of a study matters
Translational Cancer Research
2016;
5
(Suppl 3)
:S590-S594
.
(29 September 2016)
Signals derived from the commensal microbiota to promote intestinal tumor development
Translational Cancer Research
2016;
5
(Suppl 3)
:S595-S597
.
(29 September 2016)
Correspondence
The driving role of cancer-testis genes: a new perspective for cancer researches
Translational Cancer Research
2016;
5
(Suppl 3)
:S598-S600
.
(29 September 2016)
Apatinib: get better application in gastric cancer and other cancers
Translational Cancer Research
2016;
5
(Suppl 3)
:S601-S603
.
(29 September 2016)
Understanding intra-tumor heterogeneity and tumor evolution to facilitate hepatocellular carcinoma therapy
Translational Cancer Research
2016;
5
(Suppl 3)
:S604-S605
.
(29 September 2016)
Emerging roles of prolactin-mediated BRCA1 function
Translational Cancer Research
2016;
5
(Suppl 3)
:S606-S607
.
(29 September 2016)
Biomarkers France: a first and distinctive step in assessing the impact of non-small cell lung cancer (NSCLC) patients routine molecular profiling
Translational Cancer Research
2016;
5
(Suppl 3)
:S608-S609
.
(29 September 2016)
Canine factor VII deficiency as a test-platform to evaluate FVII gene therapy in humans
Translational Cancer Research
2016;
5
(Suppl 3)
:S610-S612
.
(29 September 2016)
Long-term safety of targeted agents used to treat metastatic renal cell carcinoma: the issue is not the rate of adverse events over time, but the expertise needed to manage them
Translational Cancer Research
2016;
5
(Suppl 3)
:S613-S615
.
(29 September 2016)
Disclosure:
This supplement was published without any sponsorship or funding.
